Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model

Scott, Nick, McBryde, Emma S., Thompson, Alexander, Doyle, Joseph S., and Hellard, Margaret E. (2016) Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut. pp. 1-9.

[img] PDF (Accepted Publisher Version) - Accepted Version
Restricted to Repository staff only

View at Publisher Website:


Aims: The World Health Organisation's (WHO's) draft hepatitis C virus (HCV) elimination targets propose an 80% reduction in incidence and a 65% reduction in HCV-related deaths by 2030. We estimate the treatment scale-up required and cost-effectiveness of reaching these targets among injecting drug use (IDU)-acquired infections using Australian disease estimates.

Methods: A mathematical model of HCV transmission, liver disease progression and treatment among current and former people who inject drugs (PWID). Treatment scale-up and the most efficient allocation to priority groups (PWID or people with advanced liver disease) were determined; total healthcare and treatment costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) compared to inaction were calculated.

Results: 5,662 (95%CI 5,202-6,901) courses per year (30/1000 IDU-acquired infections) were required, prioritised to patients with advanced liver disease, to reach the mortality target. 4,725 (3,278-8,420) courses per year (59/1000 PWID) were required, prioritised to PWID, to reach the incidence target; this also achieved the mortality target, but to avoid clinically unacceptable HCV related deaths an additional 5,564 (1,959-6,917) treatments per year (30/1000 IDU-acquired infections) were required for five years for people with advanced liver disease. Achieving both targets in this way cost AUS$4.6 ($4.2-4.9) billion more than inaction, but gained 184,000 (119,000-417,000) QALYs, giving an ICER of AUS$25,121 ($11,062-39,036) per QALY gained.

Conclusions: Achieving WHO elimination targets with treatment scale-up is likely to be cost-effective, based on Australian HCV burden and demographics. Reducing incidence should be a priority to achieve both WHO elimination goals in the long-term.

Item ID: 44116
Item Type: Article (Research - C1)
ISSN: 1468-3288
Funders: Victorian Infectious Diseases Service Special Purpose Fund at Melbourne Health (VIDS), Victorian Government Operational Infrastructure Support Program (VGOISP), Burnet Institute (BI), National Health and Medical Research Council (NHMRC)
Date Deposited: 12 Aug 2016 01:50
FoR Codes: 32 BIOMEDICAL AND CLINICAL SCIENCES > 3202 Clinical sciences > 320211 Infectious diseases @ 50%
44 HUMAN SOCIETY > 4407 Policy and administration > 440706 Health policy @ 50%
SEO Codes: 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920109 Infectious Diseases @ 50%
92 HEALTH > 9202 Health and Support Services > 920207 Health Policy Evaluation @ 50%
Downloads: Total: 4
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page